[摘要]目的 探討唑来膦酸注射液联合钙尔奇D治疗糖尿病骨质疏松的临床效果及安全性。方法 选择2012年4月～2016年4月我院收治的77例糖尿病骨质疏松症患者为研究对象，按随机数字表法分组，观察组39例，对照组38例，对照组采用常规降糖治疗联合钙尔奇D治疗，观察组在对照组基础上加用唑来膦酸注射液，对两组患者治疗后骨密度变化、骨代谢情况、不良反应等进行观察。结果 治疗前，两组患者股骨颈、腰椎骨、Ward′s三角区的骨密度无明显差异(P>0.05)，治疗后，两组患者骨密度水平均有改善，观察组治疗后骨密度明显较对照组高，差异有统计学意义(P0.05)，治疗后，对照组ALP低于治疗前，其余指标无明显差异(P>0.05)，观察组治疗后各项指标均有变化，与对照组对比差异有统计学意义(P0.05)，after the treatment，the bone mineral density levels of two groups of patients were improved，and the bone mineral density after treatment in the observation group was significantly higher than that of the control group，the difference was statistically significant(P0.05)，after the treatment，the ALP in the control group was lower than that before treatment， and there was no significant difference between the other indexes(P>0.05)，and the changes of the indexes in the observation group were statistically significant compared with the control group(P, 百拇医药(黄冰) 第 1 2 3 页 下一页
 百拇医药网 http://www.100md.com/html/paper/1674-4721/2017/16/06.htm